MLAB · XBRL financial data

Mesa Laboratories financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MLAB's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue from contracts with customers	133,937	184,335	219,080	216,187	240,978	249,130
Cost of revenue	46,923	75,245	85,387	82,937	90,108	90,860
Gross profit	87,014	109,090	133,693	133,250	150,870	158,270
Research and development	10,388	15,767	20,490	19,300	19,518	20,308
General and administrative	45,697	60,311	72,444	72,867	73,333	78,658
Total operating expenses	74,656	104,388	130,373	405,325	134,534	139,759
Operating income (loss)	12,358	4,702	3,320	(272,075)	16,336	18,511
Interest income	107	—	—	—	—	—
Interest expense	8,024	3,885	4,770	5,697	11,859	10,692
Other income (expense)	(2,138)	2,757	1,061	2,124	(1,403)	4,195
Income tax expense (benefit)	(971)	1,703	(1,319)	(21,402)	7,935	5,302
Net income (loss)	3,274	1,871	930	(254,246)	(1,974)	6,712
Earnings per share, basic USD per share	0.66	0.36	0.17	(47.20)	(0.36)	1.22
Earnings per share, diluted USD per share	0.64	0.35	0.17	(47.20)	(0.36)	1.21
Weighted average shares, basic thousands of shares	4,975	5,212	5,321	5,386	5,421	5,514
Weighted average shares, diluted thousands of shares	5,124	5,335	5,361	5,386	5,421	5,565

Fiscal years (MLAB's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	263,865	49,346	32,910	28,214	27,321	26,928
Accounts receivable	23,787	41,224	42,551	39,055	41,970	44,099
Inventory	11,178	24,606	34,642	32,675	25,365	26,373
Prepaid and other current assets	837	9,142	8,872	9,408	8,029	8,868
Total current assets	303,749	124,318	118,975	109,352	102,685	106,268
Property and equipment, net	21,998	28,620	28,149	31,766	32,333	30,613
Right-of-use asset	—	—	8,693	9,671	16,382	17,500
Goodwill	160,841	291,166	286,444	180,096	181,760	186,863
Total assets	601,475	707,369	661,832	446,796	433,348	427,747
Accounts payable	4,473	7,897	6,134	6,041	5,747	4,928
Accrued liabilities	8,297	11,611	13,385	12,858	24,601	17,616
Total current liabilities	32,583	48,055	43,359	44,312	163,963	61,898
Lease liability, non-current	—	—	5,752	6,613	12,380	13,662
Total liabilities	195,248	313,568	268,352	301,403	273,518	241,502
Retained earnings (accumulated deficit)	72,459	76,675	74,199	(183,494)	(188,936)	(185,747)
Total stockholders' equity	406,227	393,801	393,480	145,393	159,830	186,245
Total liabilities and equity	601,475	707,369	661,832	446,796	433,348	427,747
Common shares outstanding (cover page) thousands of shares	5,141	5,268	5,370	5,409	5,455	5,525

Fiscal years (MLAB's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	3,274	1,871	930	(254,246)	(1,974)	6,712
Stock-based compensation	9,268	11,391	12,538	11,936	13,142	17,868
Depreciation and amortization	17,660	25,068	33,824	—	—	—
Net cash from operating activities	37,073	39,223	27,983	44,133	46,808	42,831
Purchases of property and equipment	1,992	4,432	4,544	2,567	4,249	3,250
Net cash from investing activities	(1,992)	(305,225)	(9,494)	(81,306)	(4,499)	(3,250)
Proceeds from issuing common stock	145,935	0	0	—	—	—
Dividends paid	3,165	3,339	3,406	3,447	3,468	3,523
Net cash from financing activities	146,228	52,576	(33,328)	32,836	(44,509)	(41,854)
Net change in cash	182,485	(214,519)	(16,436)	(4,696)	(893)	(393)

SIC 3823 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3823 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Mesa Laboratories	30,695	60,138	14,736	5.6M	—	Q1 FY27 10-QJun 30, 2026
Pacific Biosciences of California	61,003	39,007	(35,583)*	310.8M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Senseonics Holdings	44,753	14,483	(30,138)*	52.9M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Cytek Biosciences	73,846	48,140	1,367*	130.0M	—	Q2 FY26 10-QJun 30, 2026
Quantum-Si	23,653	344	(18,444)*	not reported	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Crawford United	1,923	not reported	5,706*	not reported	—	Q3 FY25 10-QSep 30, 2025
Allient	42,088	153,770	13,954*	17.0M	—	Q2 FY26 10-QJun 30, 2026
Frequency Electronics	61,407	23,451	2,622	11.3M	—	Q1 FY27 10-QJul 31, 2026
Quanterix	44,169	32,906	(5,119)*	47.3M	18.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.